Valuation
$10B
Basis and date
Funding round · Jan 1, 2025
Rank by valuation
#60
Sector · country
Biotechnology · United States
Employees
170 (2025)
Valuation history
| Date | Basis | Valuation | Source |
|---|---|---|---|
| Jan 1, 2025 | Funding round | $10B | Colossal Biosciences Raises $200 Million, Hits $10.2 Billion Valuation in Push to Revive Extinct Species ↗ |
The latest reported valuation, with the report it came from.
Funding rounds filed with the SEC
| First sale | Amount sold | Offering size | Investors | Security |
|---|---|---|---|---|
| Jan 27, 2023 | $150M | $150M | 15 | Equity |
From the company’s Form D notices (SEC filings ↗). Form D reports the amount sold, not the valuation or the investors’ names.
Executives and directors
- class=nowrap| Ben Lamm (CEO) |Beth Shapiro (CSO)|Andrew Pask (Chief biology officer)}} (Wikipedia)
- Brian Beard · Executive Officer, Director (SEC Form D)
Founders
George Church, Ben Lamm
IPO status
Not on the IPO Calendar.
Valuations are point-in-time marks, not trading prices, and private shares are not generally available to retail investors. Data: Wikipedia’s list of unicorn startup companies and the company’s article (CC BY-SA 4.0), and SEC Form D filings, company article. Last updated Nov 13, 2026. This is historical data, not investment advice. Report a data error